Lophora Secures $3 Million in Funding for Groundbreaking Psychedelic Medicine Development

Lophora, a pioneering clinical-stage CNS drug discovery company founded in 2018, is thrilled to announce the successful raising of $3 million in funding to advance its innovative pipeline of next-generation psychedelic medicines designed to treat a range of psychiatric disorders.

This significant investment comes from a combination of public sources and seasoned biotech investors, reflecting an increasing confidence in Lophora’s approach to mental health therapies.

The funding will enable the company to kickstart its first-in-human trials for its lead candidate, LPH-5, with initial trials set to begin in 2024.

LPH-5's efficacy has been comprehensively characterized through extensive in vivo studies and has successfully completed GLP-Tox, paving the way for anticipated Clinical Trial Application (CTA) submission by Q2 2024.

Lophora is dedicated to transforming the landscape of psychiatric treatment through its cutting-edge research, driven by a commitment to addressing the pressing mental health needs of millions.

With this new capital injection, Lophora is well-positioned to further advance its groundbreaking work, ultimately aiming to provide new hope for individuals seeking effective solutions for their mental health struggles.

As the company forges ahead, it remains steadfast in its mission to develop safe, effective, and accessible therapies that have the potential to reshape psychiatric treatment for the better.

For more information on Lophora and its initiatives, visit www.lophora.com.